Cutaneous vasculitis: diagnosis and management

Clinics in Dermatology

Volumn 24, Issue 5, 2006, Pages 414-429

  Carlson, J Andrew ^a   Cavaliere, L Frank ^a   Grant Kels, Jane M ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DNA ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LA ANTIBODY; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AMYLOIDOSIS; ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; AORTA ARCH SYNDROME; ARTICLE; B CELL LYMPHOMA; BACTERIAL ENDOCARDITIS; BEHCET DISEASE; CALCINOSIS; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COCAINE DEPENDENCE; COLD EXPOSURE; CRYOGLOBULINEMIA; DISEASE CLASSIFICATION; DRUG USE; FIBROMUSCULAR DYSPLASIA; FULMINATING PURPURA; GIANT CELL ARTERITIS; HEART MYXOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; LEUKOCYTOCLASTIC VASCULITIS; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PIGMENTED PURPURIC DERMATOSIS; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; RISK FACTOR; SCURVY; SKIN BIOPSY; SKIN TUBERCULOSIS; SMALL VESSEL VASCULITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT PLANNING; VASCULITIS; WARMING; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; SKIN; SKIN DISEASES; TEMPERATURE; VASCULITIS;

EID: 33748328144     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.07.007     Document Type: Article

References (170)

1. Carlson J.A., Ng B.T., and Chen K.R. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 27 (2005) 504-528
2. Sorensen S.F., Slot O., Tvede N., and Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 59 (2000) 478-482
3. Guillevin L., Lhote F., Amouroux J., Gherardi R., Callard P., and Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis nodosa group. Br J Rheumatol 35 (1996) 958-964
4. Rao J.K., Allen N.B., and Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 129 (1998) 345-352
5. Jennette C.J., Milling D.M., and Falk R.J. Vasculitis affecting the skin. A review. Arch Dermatol 130 (1994) 899-906
6. Lane S.E., Watts R.A., Shepstone L., and Scott D.G. Primary systemic vasculitis: clinical features and mortality. QJM 98 (2005) 97-111
7. Lane S.E., Watts R.A., Barker T.H., and Scott D.G. Evaluation of the Sorensen diagnostic criteria in the classification of systemic vasculitis. Rheumatology (Oxford) 41 (2002) 1138-1141
8. Watts R.A., Jolliffe V.A., Carruthers D.M., Lockwood M., and Scott D.G. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 39 (1996) 1208-1212
9. Sais G., Vidaller A., Jucgla A., Servitje O., Condom E., and Peyri J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 134 (1998) 309-315
10. Helander S.D., De Castro F.R., and Gibson L.E. Henoch-Schonlein purpura: clinicopathologic correlation of cutaneous vascular IgA deposits and the relationship to leukocytoclastic vasculitis. Acta Derm Venereol 75 (1995) 125-129
11. Barnadas M.A., Perez E., Gich I., et al. Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol 43 (2004) 19-26
12. Magro C.M., and Crowson A.N. A clinical and histologic study of 37 cases of immunoglobulin A-associated vasculitis. Am J Dermatopathol 21 (1999) 234-240
13. Stone J.H., and Nousari H.C. "Essential" cutaneous vasculitis: what every rheumatologist should know about vasculitis of the skin. Curr Opin Rheumatol 13 (2001) 23-34
14. Russell J.P., and Gibson L.E. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 45 (2006) 3-13
15. Carlson J.A., and Chen K.R. Cutaneous vasculitis update: specific vasculitic syndromes. Am J Dermatopathol (2006) [in press]
16. Grau R. Pseudovasculitis: mechanisms of vascular injury and clinical spectrum. Curr Rheumatol Rep 4 (2002) 83-89
17. Gibson L.E., Specks U., and Homburger H. Clinical utility of ANCA tests for the dermatologist. Int J Dermatol 42 (2003) 859-869
18. Schmitt W.H., and van der Woude F.J. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol 16 (2004) 9-17
19. Merkel P.A., Polisson R.P., Chang Y., Skates S.J., and Niles J.L. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126 (1997) 866-873
20. Vassilopoulos D., Niles J.L., Villa-Forte A., et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 49 (2003) 151-155
21. Watts R.A., Jolliffe V.A., Grattan C.E., Elliott J., Lockwood M., and Scott D.G. Cutaneous vasculitis in a defined population-clinical and epidemiological associations. J Rheumatol 25 (1998) 920-924
22. Gonzalez-Gay M.A., and Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain. Clinical and epidemiologic aspects. Medicine (Baltimore) 78 (1999) 292-308
23. Winkelmann R.K., and Ditto W.B. Cutaneous and visceral syndromes of necrotizing or "allergic" angiitis: a study of 38 cases. Medicine (Baltimore) 43 (1964) 59-89
24. Saleh A., and Stone J.H. Classification and diagnostic criteria in systemic vasculitis. Best Pract Res Clin Rheumatol 19 (2005) 209-221
25. Ratnam K.V., Boon Y.H., and Pang B.K. Idiopathic hypersensitivity vasculitis: clinicopathologic correlation of 61 cases. Int J Dermatol 34 (1995) 786-789
26. Ioannidou D.J., Krasagakis K., Daphnis E.K., Perakis K.E., Sotsiou F., and Tosca A.D. Cutaneous small vessel vasculitis: an entity with frequent renal involvement. Arch Dermatol 138 (2002) 412-414
27. Tancrede-Bohin E., Ochonisky S., Vignon-Pennamen M.D., Flageul B., Morel P., and Rybojad M. Schonlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol 133 (1997) 438-442
28. Hodge S.J., Callen J.P., and Ekenstam E. Cutaneous leukocytoclastic vasculitis: correlation of histopathological changes with clinical severity and course. J Cutan Pathol 14 (1987) 279-284
29. Sanchez N.P., Van Hale H.M., and Su W.P. Clinical and histopathologic spectrum of necrotizing vasculitis. Report of findings in 101 cases. Arch Dermatol 121 (1985) 220-224
30. Lerner L., Lio P., and Flotte T. The prognostic significance of vascular immunoglobulin deposits in 94 cases of cutaneous leukocytoclastic vasculitis. J Cutan Pathol 27 (2000) 562
31. Sais G., Vidaller A., Servitje O., Jucgla A., and Peyri J. Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin. J Allergy Clin Immunol 98 (1996) 232-233
32. Mehregan D.R., Hall M.J., and Gibson L.E. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 26 3 Pt 2 (1992) 441-448
33. Davis M.D., Daoud M.S., Kirby B., Gibson L.E., and Rogers III R.S. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol 38 6 Pt 1 (1998) 899-905
34. Sunderkotter C., Seeliger S., Schonlau F., et al. Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol 10 (2001) 391-404
35. Kim S.H., Kim T.B., Yun Y.S., et al. Hypereosinophilia presenting as eosinophilic vasculitis and multiple peripheral artery occlusions without organ involvement. J Korean Med Sci 20 (2005) 677-679
36. Chen K.R., Su W.P.D., Pittelkow M.R., Conn D.L., George T., and Leiferman K.M. Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol 35 2 Pt 1 (1996) 173-182
37. Ma-Krupa W., Jeon M.S., Spoerl S., Tedder T.F., Goronzy J.J., and Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199 (2004) 173-183
38. Carlson J.A., Mihm Jr. M.C., and LeBoit P.E. Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Semin Diagn Pathol 13 (1996) 72-90
39. Haas M., Kraus E.S., Samaniego-Picota M., Racusen L.C., Ni W., and Eustace J.A. Acute renal allograft rejection with intimal arteritis: histologic predictors of response to therapy and graft survival. Kidney Int 61 (2002) 1516-1526
40. Mihatsch M.J., Nickeleit V., and Gudat F. Morphologic criteria of chronic renal allograft rejection. Transplant Proc 31 (1999) 1295-1297
41. Kao A.H., Sabatine J.M., and Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 15 (2003) 519-527
42. Luqmani R.A., Pathare S., and Kwok-Fai T.L. How to diagnose and treat secondary forms of vasculitis. Best Pract Res Clin Rheumatol 19 (2005) 321-336
43. Gell P., and Coombs R. Clinical aspects of immunology. 1st ed (1963), Blackwell, Oxford
44. Sell S. Immunopathology. In: Sell S. (Ed). Immunology, immunopathology and immunity. 6th ed (2003), ASM, Washington (DC) 235-239
45. Arthus M. Injections repetees de serum de cheval chez le lapin. V R Soc Biol 55 (1903) 817-820
46. Wilson C.B., and Dixon F.J. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med 134 3 Suppl (1971) 7s-8s
47. Fernandez H.N., Henson P.M., Otani A., and Hugli T.E. Chemotactic response to human C3a and C5a anaphylatoxins: I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol 120 (1978) 109-115
48. Baumann U., Kohl J., Tschernig T., et al. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J Immunol 164 (2000) 1065-1070
49. Hopken U.E., Lu B., Gerard N.P., and Gerard C. Impaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor. J Exp Med 186 (1997) 749-756
50. Sylvestre D.L., and Ravetch J.V. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265 (1994) 1095-1098
51. Baumann U., Chouchakova N., Gewecke B., et al. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J Immunol 167 (2001) 1022-1027
52. Schiller C., Janssen-Graalfs I., Baumann U., et al. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol 30 (2000) 481-490
53. Kaburagi Y., Hasegawa M., Nagaoka T., et al. The cutaneous reverse Arthus reaction requires intercellular adhesion molecule 1 and l-selectin expression. J Immunol 168 (2002) 2970-2978
54. Zhang Y., Ramos B.F., and Jakschik B.A. Augmentation of reverse Arthus reaction by mast cells in mice. J Clin Invest 88 (1991) 841-846
55. Yanaba K., Kaburagi Y., Takehara K., Steeber D.A., Tedder T.F., and Sato S. Relative contributions of selectins and intercellular adhesion molecule-1 to tissue injury induced by immune complex deposition. Am J Pathol 162 (2003) 1463-1473
56. Yanaba K., Komura K., Horikawa M., Matsushita Y., Takehara K., and Sato S. P-Selectin glycoprotein ligand-1 is required for the development of cutaneous vasculitis induced by immune complex deposition. J Leukoc Biol 76 (2004) 374-382
57. Burrows N.P., Molina F.A., Terenghi G., et al. Comparison of cell adhesion molecule expression in cutaneous leucocytoclastic and lymphocytic vasculitis. J Clin Pathol 47 (1994) 939-944
58. Sais G., Vidaller A., Jucgla A., Condom E., and Peyri J. Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis. An immunohistologic and clinical study in 42 patients. Arch Dermatol 133 (1997) 443-450
59. Bielsa I., Carrascosa J.M., Hausmann G., and Ferrandiz C. An immunohistopathologic study in cutaneous necrotizing vasculitis. J Cutan Pathol 27 (2000) 130-135
60. Cid M.C., Cebrian M., Font C., et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 43 (2000) 184-194
61. Coll-Vinent B., Cebrian M., Cid M.C., et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 41 (1998) 435-444
62. Inaloz H.S., Evereklioglu C., Unal B., Kirtak N., Eralp A., and Inaloz S. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behcet's syndrome. J Eur Acad Dermatol Venereol 18 (2004) 56-61
63. Kano Y., Orihara M., and Shiohara T. Cellular and molecular dynamics in exercise-induced urticarial vasculitis lesions. Arch Dermatol 134 (1998) 62-67
64. Sais G., and Vidaller A. Pathogenesis of exercise-induced urticarial vasculitis lesions: can the changes be extrapolated to all leukocytoclastic vasculitis lesions?. Arch Dermatol 135 (1999) 87-89
65. Cid M.C. Endothelial cell biology, perivascular inflammation, and vasculitis. Cleve Clin J Med 69 Suppl 2 (2002) SII45-SII49
66. Hernandez-Rodriguez J., Segarra M., Vilardell C., et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43 (2004) 294-301
67. Papi M., Didona B., De Pita O., et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol 134 (1998) 447-452
68. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110 (2002) 955-963
69. Day C.J., Hewins P., and Savage C.O. New developments in the pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol 21 6 Suppl 32 (2003) S35-S48
70. Marinaki S., Neumann I., Kalsch A.I., et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 140 (2005) 181-191
71. Cid M.C., Segarra M., Garcia-Martinez A., and Hernandez-Rodriguez J. Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Curr Rheumatol Rep 6 (2004) 184-194
72. Sable-Fourtassou R., Cohen P., Mahr A., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 (2005) 632-638
73. Kelly R.I., Opie J., and Nixon R. Golfer's vasculitis. Australas J Dermatol 46 (2005) 11-14
74. Ryan T. Cutaneous vasculitis. In: Champion R., Burton J., Burns D., and Breathnach S.M. (Eds). Textbook of dermatology. 6th ed (1998), Blackwell Scientific Publications, Oxford 2155-2225
75. Prins M., Veraart J.C., Vermeulen A.H., Hulsmans R.F., and Neumann H.A. Leucocytoclastic vasculitis induced by prolonged exercise. Br J Dermatol 134 (1996) 915-918
76. Langford C.A. 15. Vasculitis. J Allergy Clin Immunol 111 2 Suppl (2003) S602-S612
77. Jennette J.C. Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis. Clevel Clin J Med 69 Suppl 2 (2002) SII33-SII38
78. Harper L., Williams J.M., and Savage C.O. The importance of resolution of inflammation in the pathogenesis of ANCA-associated vasculitis. Biochem Soc Trans 32 (2004) 502-506
79. Bacon P.A. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 352 (2005) 330-332
80. Buckley C.D., Rainger G.E., Nash G.B., and Raza K. Endothelial cells, fibroblasts and vasculitis. Rheumatology (Oxford) 44 (2005) 860-863
81. Mekkes J.R., Loots M.A., van der Wal A.C., and Bos J.D. Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol 50 (2004) 104-107
82. Claudy A. Coagulation and fibrinolysis in cutaneous vasculitis. Clin Dermatol 17 (1999) 615-618
83. Tomizawa K., Sato-Matsumura K.C., and Kajii N. The coexistence of cutaneous vasculitis and thrombosis in childhood-onset systemic lupus erythematosus with antiphospholipid antibodies. Br J Dermatol 149 (2003) 439-441
84. Rocca P.V., Siegel L.B., and Cupps T.R. The concomitant expression of vasculitis and coagulopathy: synergy for marked tissue ischemia. J Rheumatol 21 (1994) 556-560
85. Weidner S., Hafezi-Rachti S., and Rupprecht H.D. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 55 (2006) 146-149
86. Rees J.D., Lanca S., Marques P.V., et al. Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis 65 (2006) 109-111
87. Diaz-Perez J.L., Schroeter A.L., and Winkelmann R.K. Cutaneous periarteritis nodosa: immunofluorescence studies. Arch Dermatol 116 (1980) 56-58
88. Drenkard C., Villa A.R., Reyes E., Abello M., and Alarcon-Segovia D. Vasculitis in systemic lupus erythematosus. Lupus 6 (1997) 235-242
89. Fiorentino D.F. Cutaneous vasculitis. J Am Acad Dermatol 48 (2003) 311-340
90. Gonzalez-Gay M.A., Garcia-Porrua C., and Pujol R.M. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol 17 (2005) 56-61
91. Luqmani R.A. Is it possible to offer evidence-based treatment for systemic vasculitis?. Scand J Rheumatol 29 (2000) 211-215
92. Russell J.P., and Weenig R.H. Primary cutaneous small vessel vasculitis. Curr Treat Options Cardiovasc Med 6 (2004) 139-149
93. Callen J.P. A clinical approach to the vasculitis patient in the dermatologic office. Clin Dermatol 17 (1999) 549-553
94. Luqmani R.A., Bacon P.A., Moots R.J., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87 (1994) 671-678
95. Exley A.R., Bacon P.A., Luqmani R.A., Kitas G.D., Carruthers D.M., and Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 37 (1998) 57-63
96. Guillevin L., Lhote F., Leon A., Fauvelle F., Vivitski L., and Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 20 (1993) 289-298
97. Newburger J.W., Takahashi M., Burns J.C., et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315 (1986) 341-347
98. Callen J.P., and Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J 80 (1987) 848-851
99. Ramelli G.P., and Bianchetti M.G. Dapsone in cutaneous Henoch-Schonlein syndrome-worth a trial. Acta Paediatr 86 (1997) 337
100. Fredenberg M.F., and Malkinson F.D. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 16 (1987) 772-778
101. Callen J.P. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 13 2 Pt 1 (1985) 193-200
102. Nurnberg W., Grabbe J., and Czarnetzki B.M. Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis. Lancet 343 (1994) 491
103. Nurnberg W., Grabbe J., and Czarnetzki B.M. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol 75 (1995) 54-56
104. Sais G., Vidaller A., Jucgla A., Gallardo F., and Peyri J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 131 (1995) 1399-1402
105. Sharquie K.E., Najim R.A., and Abu-Raghif A.R. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29 (2002) 267-279
106. Ferri C., Pietrogrande M., Cecchetti R., et al. Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med 87 (1989) 519-524
107. Lunardi C., Bambara L.M., Biasi D., Zagni P., Caramaschi P., and Pacor M.L. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol 10 (1992) 131-135
108. Cupps T.R., Springer R.M., and Fauci A.S. Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients. JAMA 247 (1982) 1994-1998
109. Quintana G., Matteson E.L., Fernandez A., Restrepo J.F., and Iglesias A. Localized nodular vasculitis: a new variant of localized cutaneous polyarteritis nodosa?. Clin Exp Rheumatol 22 6 Suppl 36 (2004) S31-S34
110. Jorizzo J.L., White W.L., Wise C.M., Zanolli M.D., and Sherertz E.F. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcet's disease. J Am Acad Dermatol 24 6 Pt 1 (1991) 973-978
111. Williams H.C., and Pembroke A.C. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. J R Soc Med 82 (1989) 763
112. Upchurch K.S., Heller K., and Bress N.M. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 17 2 Pt 2 (1987) 355-359
113. Wilson K., and Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 21 (1994) 1674-1677
114. Gansauge S., Breitbart A., Rinaldi N., and Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 56 (1997) 382-385
115. ten Holder S.M., Joy M.S., and Falk R.J. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 36 (2002) 130-147
116. Kaye O., Beckers C.C., Paquet P., Arrese J.E., Pierard G.E., and Malaise M.G. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 23 (1996) 253-257
117. Callen J.P., Spencer L.V., Burruss J.B., and Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127 (1991) 515-522
118. Martinez-Taboada V.M., Blanco R., Garcia-Fuentes M., and Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 102 (1997) 186-191
119. Lopez L.R., Davis K.C., Kohler P.F., and Schocket A.L. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol 73 5 Pt 1 (1984) 600-603
120. Tsakonas E., Joseph L., Esdaile J.M., et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7 (1998) 80-85
121. Tosca A.D., Ioannidou D.J., Katsantonis J.C., and Kyriakis K.P. Cyclosporin A in the treatment of cutaneous vasculitis. Clinical and cellular effects. J Eur Acad Dermatol Venereol 6 (1996) 135-141
122. Stratigos J.D., Katsambas A., and Potouridou E. Cyclosporin-a therapy for allergic cutaneous vasculitis. J Dermatol Treat 5 (1994) 93-95
123. de Groot K., and Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 64 (2005) 480-484
124. Singh S., Devidayal, Kumar L., Joshi K., Minz R.W., and Datta U. Severe Henoch-Schonlein nephritis: resolution with azathioprine and steroids. Rheumatol Int 22 (2002) 133-137
125. Worm M., Sterry W., and Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 143 (2000) 1324
126. Gaskin G., and Pusey C.D. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 5 (2001) 176-181
127. Turner A.N., Whittaker S., Banks I., Jones R.R., and Pusey C.D. Plasma exchange in refractory cutaneous vasculitis. Br J Dermatol 122 (1990) 411-415
128. Gedalia A., and Sorensen R. Intravenous immunoglobulin in childhood cutaneous polyarteritis nodosa. Clin Exp Rheumatol 16 (1998) 767
129. Ong C.S., and Benson E.M. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 143 (2000) 447-449
130. Aries P.M., Hellmich B., and Gross W.L. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?. Clin Rev Allergy Immunol 29 (2005) 237-245
131. Buhaescu I., Covic A., and Levy J. Systemic vasculitis: still a challenging disease. Am J Kidney Dis 46 (2005) 173-185
132. Mukhtyar C., and Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis 64 Suppl 4 (2005) iv31-iv36
133. Lamprecht P. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev 4 (2005) 28-34
134. Cohen S.B. B-Cell depletion for rheumatic diseases: where are we?. Med Gen Med 7 (2005) 72
135. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 117 (2005) 207-213
136. Raza K., Carruthers D.M., Stevens R., Filer A.D., Townend J.N., and Bacon P.A. Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. Ann Rheum Dis 65 (2006) 946-948
137. Booth A.D., Jayne D.R., Kharbanda R.K., et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109 (2004) 1718-1723
138. Lamprecht P., Voswinkel J., Lilienthal T., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41 (2002) 1303-1307
139. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
140. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
141. van der Bijl A.E., Allaart C.F., Van Vugt J., Van Duinen S., and Breedveld F.C. Rheumatoid vasculitis treated with infliximab. J Rheumatol 32 (2005) 1607-1609
142. Uthman I.W., Touma Z., Sayyad J., and Salman S. Response of deep cutaneous vasculitis to infliximab. J Am Acad Dermatol 53 (2005) 353-354
143. Leiba M., and Ehrenfeld M. Behcet's disease: current therapeutic perspectives. Curr Treat Options Cardiovasc Med 7 (2005) 139-148
144. Armstrong D.J., McCarron M.T., and Wright G.D. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol 32 (2005) 759 [author reply 759-60]
145. Mang R., Ruzicka T., and Stege H. Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol 51 (2004) 321-322
146. Chandesris M.O., Gayet S., Schleinitz N., Doudier B., Harle J.R., and Kaplanski G. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology (Oxford) 43 (2004) 532-533
147. Unger L., Kayser M., and Nusslein H.G. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 62 (2003) 587-588
148. Gulli S., Arrigo C., Bocchino L., et al. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 4 (2003) 19
149. Garcia-Porrua C., and Gonzalez-Gay M.A. Successful response to infliximab in a patient with undifferentiated spondyloarthropathy coexisting with polyarteritis nodosa-like cutaneous vasculitis. Clin Exp Rheumatol 21 6 Suppl 32 (2003) S138
150. Stone J.H. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
151. Feinstein J., and Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 11 (2005) 219-222
152. Atzeni F., Sarzi-Puttini P., Capsoni F., Mecchia M., Marrazza M.G., and Carrabba M. Successful treatment of resistant Behcet's disease with etanercept. Clin Exp Rheumatol 23 (2005) 729
153. Melikoglu M., Fresko I., Mat C., et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 32 (2005) 98-105
154. Tan A.L., Holdsworth J., Pease C., Emery P., and McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62 (2003) 373-374
155. Scheinberg M.A. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 20 (2002) 733-734
156. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
157. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., and Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003) 3818-3826
158. Koukoulaki M., Abeygunasekara S.C., Smith K.G., and Jayne D.R. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 20 (2005) 213-216
159. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257 (2005) 540-548
160. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
161. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
162. Ferri C., and Mascia M.T. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18 (2006) 54-63
163. Roccatello D., Baldovino S., Rossi D., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19 (2004) 3054-3061
164. Saigal K., Valencia I.C., Cohen J., and Kerdel F.A. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol 49 5 Suppl (2003) S283-S285
165. Guillevin L., and Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 31 (2004) 1885-1887
166. Srivastava M.D., Alexander F., and Tuthill R.J. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 61 (2005) 329-336
167. Jarrett S.J., Cunnane G., Conaghan P.G., et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30 (2003) 2287-2291
168. Mohan N., Edwards E.T., Cupps T.R., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31 (2004) 1955-1958
169. Kandula P., and Kouides P.A. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol 142 (2006) 246-247
170. Dereure O., Navarro R., Rossi J.F., and Guilhou J.J. Rituximab-induced vasculitis. Dermatology 203 (2001) 83-84